Background: Owing to the emergence of multiresistant Plasmodium falciparum parasites in Southeast Asia, along with the impressive decrease in the efficacy of the endoperoxide compound artemisinin and of artemisinin-based combination therapies, the development of novel antimalarial drugs or combinations is required. Although several antiplasmodial molecules, such as endoperoxide-based compounds, are in advanced research or development, we do not know whether resistance to artemisinin derivatives might impact the efficacy of these new compounds.
Introduction
The recent emergence of artemisinin-and partner drug-(mefloquine and piperaquine) resistant P. falciparum parasites in Southeast Asia heavily impacts the efficacy of the artemisininbased combination therapies, which are currently recommended to treat uncomplicated falciparum malaria. In recent studies in parts of Cambodia with known artemisinin resistance, 10%-60% of subjects treated with dihydroartemisinin/piperaquine experienced treatment failure. [1] [2] [3] In this context, new antimalarial drugs and new combinations are urgently needed. Many antiplasmodial molecules in development or already approved by national regulators are endoperoxide-based compounds. 4 At present, the efficacy of these new endoperoxide-based antimalarials on artemisininresistant P. falciparum parasites has not been fully explored and the ability of these new compounds to select for resistant parasites in vitro is not known. Among innovative antiplasmodial and endoperoxide-based drug candidates, trioxaquines 5, 6 appear to be a relevant tool to study endoperoxide-based compounds. Indeed, these drugs are not toxic to cell lines or in mouse models and are extremely active both in vitro and in vivo against: (i) all malaria blood stages (including gametocytes); and (ii) a large panel of P. falciparum strains and isolates. [7] [8] [9] [10] [11] [12] This chemical class of hybrid molecules is composed of a quinoline (as in chloroquine, amodiaquine, mefloquine or primaquine) and 1,2,4-trioxane (as in artemisinin and its derivatives) moieties, and it can mimic combination therapies with an artemisinin derivative and a partner drug. The dual and complementary mode of action of both compounds is expected to prevent the risk of selection of resistant parasites. 13, 14 Previous investigations have shown the absence of crossresistance between chloroquine and trioxaquines despite their common quinoline entity. [9] [10] [11] We evaluated whether artemisinin-resistant parasites could be eliminated by trioxaquines. We used different in vitro assays to determine the susceptibility of F32-ART5, an artemisinin-resistant P. falciparum laboratory line, 15, 16 and recent Cambodian field isolates, to artemisinin and different trioxaquines (DU1302, DU2302, DU2303, PA1103) and to their respective quinoline and trioxane moieties. In parallel, the F32-DU parasite line was selected by culturing the F32-Tanzania clone under a 4 year dose-escalating pressure of trioxaquine DU1302; its susceptibility to artemisinin and trioxaquines was assessed. Whole-genome sequences obtained from the control line F32-TEM (cultured without any drug pressure) and F32-DU were compared to explore molecular signatures associated with the resistance to trioxane compounds.
Materials and methods

Drugs
Trioxaquines [DU1302 (molecular weight 870.3), PA1103 (MW 480.2), DU2302 (MW 907.9), DU2303 (MW 596.6)], and their respective quinoline and trioxane moieties ( Figure 1 ) were synthesized as previously described. 7, 11 Extensive stability experiments and pharmacokinetics data are already published. 8, 11, 14 Chloroquine diphosphate and primaquine diphosphate were purchased from Sigma-Aldrich (Saint-Quentin-Fallavier, France), artemisinin was purchased from TCI Europe, and dihydroartemisinin was provided by the WorldWide Antimalarial Resistance Network. Drug compounds were dissolved first in DMSO or directly (for chloroquine) in RPMI-1640 medium (Biowest, France) to prepare 1 mg/mL stock solutions, and then successively diluted to appropriate concentrations in RPMI-1640 with a maximum final DMSO concentration of 1%.
Parasite cultures
Three Plasmodium falciparum parasite lines (F32-TEM, F32-ART5 and F32-DU) were cultivated as previously described by Trager and Jensen, 17 with some modifications. 9 Parasites were maintained at 37 C with 5% CO 2 in type O human red blood cells (Etablissement Français du Sang, France) diluted to 2% haematocrit in RPMI-1640 medium supplemented with 5% human serum (Etablissement Français du Sang).
A total of 115 field isolates, collected in 2011-12 from febrile patients seeking antimalarial treatment at health facilities across Cambodia (Battambang, Kampong Som, Kampong Speu, Kampong Thom, Kampot, Mondulkiri, Oddar Meanchey, Pailin, Pursat, Rattanakiri and Preah Vihear provinces), were adapted to in vitro culture as previously described 18 for a minimum of 3 weeks before proceeding with experiments.
In vitro selection of the F32-DU trioxaquine-resistant line
The parental strain used to conduct drug selection pressure experiments 19 was the mycoplasma-free F32-Tanzania clone. Discontinuous and dose-escalating DU1302 pressures were applied for . 4 years with a starting dose of 7 nM to a maximum dose of 3.5 mM ( Figure S1 , available as Supplementary data at JAC Online, and Figure 2 ). The parasite line obtained after 80 drug-pressure cycles with DU1302 was named F32-DU. The F32-ART5 line, already described, was obtained in parallel after 5 years of artemisinin sequential pressure with doses ranging from 10 nM to 18 mM. 15, 16 F32-ART5 parasites here studied were collected during the period extending from the 118th to the 129th artemisinin pressure cycle. Phenotypic and genomic characteristics of artemisinin resistance showed no differences in parasites from these drug pressure cycles. As a control, the parental strain F32-Tanzania was cultured in the same conditions of continuous culture without drug, and called F32-TEM (Figure 2 ).
Standard in vitro susceptibility assays
In vitro susceptibility of P. falciparum parasites (laboratory lines and Cambodian field isolates) was determined by using the standard hypoxanthine uptake inhibition assay as described previously by Desjardins et al. 20 with some modifications, 9 
Ring-stage survival assays
Ring-stage susceptibility to the trioxaquines PA1103 and DU1302 was determined via the ring-stage survival assay (RSA), as previously described. 21, 22 Briefly, parasites were tightly synchronized to early ringstage, aged from 0 to 3 h post-invasion (RSA 0-3h ), and then exposed for 6 h to a brief pulse of 700 nM PA1103, 700 nM DU1302 or 700 nM dihydroartemisinin (used as drug control). Parasites were washed and then cultivated for the next 66 h without drug. Survival rates were measured microscopically on Giemsa-stained thin blood smears. The parasite survival rate was calculated using the following formula:
Survival rate " parasitaemia in exposed culture/parasitaemia in nonexposed culture % 100 Parasitaemia was calculated by counting 40000 red blood cells per assay by two separate microscopists. A parasite growth rate of 2 in the non-exposed culture was deemed to validate the assay.
In vitro recrudescence assays
Resistance to artemisinin has been shown to be mediated by a parasite quiescence-based mechanism. 15, 23 As the standard susceptibility assay based on parasite growth was shown not to be relevant for the detection of quiescent parasites, in vitro drug recrudescence assays were performed to evaluate the ability of the F32-ART5 and F32-DU parasite lines to survive 48 h of drug exposure compared with the control F32-TEM parasite line. 15 ,16 D-Sorbitol-synchronized ring-stages at 3%-5% parasitaemia (2% haematocrit) were exposed to drugs for 48 h. A preliminary drug screening (range 1-fold to .100-fold the IC 50 ) enabled determination of the most appropriate antimalarial drug dose to discriminate the phenotype response of the different lines in the recrudescence assay. After drug exposure, cultures were washed with RPMI-1640 medium and placed in normal drugfree culture conditions. The parasitaemia was monitored daily to determine the time to recrudescence, defined as the time required for each parasite culture to reach the initial parasitaemia. If no parasites were observed in the following 30 days, the culture was deemed 'not recrudescent'. 16 Paloque et al. Cross-resistance to endoperoxide-based compounds JAC
WGS of the F32-DU parasite line
Parasite DNA was extracted from cultured parasites using the High Pure PCR Template Preparation Kit (Roche Diagnostics, Germany) according to the manufacturer's instructions. Whole-genome sequencing was performed via Illumina paired-reads sequencing. 22 Image analysis, base calling and error estimation were performed with the Illumina Analysis Pipeline version 1.7. Raw sequence files were filtered with the Fqquality tool. Trimmed reads from controlled Fastq files were mapped onto the P. falciparum 3D7 reference genome with the Burrows-Wheeler alignment, generating BAM files (binary files of tab-delimited format SAM). Samtools was used to prepare pileup files, which were formatted with in-house software to integrate the data into the Whole-genome Data Manager database. 24 Exomes of the parasite lines were compared after excluding positions with coverage ,25% of the genome-wide mean. Single nucleotide polymorphisms (SNPs) were explored after excluding genes from highly variable multi-gene families (var, rifin, phist and stevor), as previously described. 22 Copy number variations and SNPs (after excluding indels) were investigated with PlasmoCNVScan and Phen2 gen software. 25 Genes with nucleotide sequence lengths of ,500 bp were excluded. To ensure the absence of cross-contamination between F32-TEM, F32-ART5 and F32-DU lines, we compared the differences in terms of SNPs among the three strains.
Sequencing of the K13 propeller domain
Samples were screened for mutations in the K13 propeller domain gene 22 according to the procedure described on the Nature protocols website. 26 Briefly, the K13 propeller domain gene was amplified via a nested PCR approach. PCR products were detected using 2% agarose gel electrophoresis and ethidium bromide staining. Double-strand sequencing of PCR products was performed by Macrogen (Korea). Electropherograms were visualized and analysed with CEQ2000 genetic analysis system software (Beckman Coulter, Villepinte, France). The amino acid sequences were compared with the wild-type (WT) amino acid sequences (GenBank accession number XM_001350122). The presence of SNPs was confirmed by reading both the forward and the reverse strands. F32-TEM (K13 WT) and F32-ART5 (476I mutant allele) were used as controls. 16 
Statistical analyses
For ring-stage survival data, as recommended for improving the normality of proportion data, 27 the arcsine-square-root transformation was applied to the survival rates. A two-way analysis of variance was performed on line and molecule factors using the initial parasitaemia rate as a baseline. For each molecule, a between-lines comparison of least square means was performed, followed by a Tukey P value adjustment for multiplicity correction. For in vitro recrudescence times, given the low number of experiments by samples, a descriptive approach is preferred. Nevertheless, a one-sided WilcoxonMann-Whitney (two-sample rank) test of superiority to 3 was used to compare the recrudescence time medians between the lines. A Kaplan-Meier survival analysis was performed on in vitro recrudescence data. The final event was defined as the time to recrudescence to reach day zero (D0) Paloque et al. Table 1 .
Cross-resistance to endoperoxide-based compounds JAC parasitaemia. Observations were considered censored if no recrudescence was observed during the experiment time frame (30 days). For F32-ART5 versus F32-DU comparisons, the Wilcoxon-Mann-Whitney was performed on the absolute values. P values obtained with less than five observations should be interpreted with caution. For experiments with no recrudescence observed during the experiment time frame (30 days), the recrudescence time was set to 30.
Results and discussion
Trioxaquines are highly active against artemisinin-susceptible parasites
Trioxaquines are hybrid molecules with a dual mode of action; they are composed of a quinoline moiety, such as chloroquine or amodiaquine, and a 1,2,4-trioxane moiety, as in artemisinin. 13, 14 The trioxaquines DU1302, DU2302, DU2303 and PA1103 were used in this study. Regardless of the in vitro susceptibility assays used (standard susceptibility assay, RSA or in vitro recrudescence assay), trioxaquines showed antimalarial activity close to the efficacy reported for the reference compounds dihydroartemisinin and artemisinin against artemisinin-susceptible parasites (see results obtained with the control susceptible line F32-TEM and the clinical field isolates K13 WT in Tables S1 and S2 ). We then explored whether these hybrid molecules are efficient against artemisinin-resistant parasites. However, the standard in vitro susceptibility assay is not appropriate for the detection of endoperoxide-based drug resistance as already reported. 15, 16, 18 The median IC 50 values of such drugs did not significantly differ between K13 WT and K13 mutant laboratory strains (Table S1 ) or recent Cambodian isolates (Table S2) , and the use of recrudescence and RSAs was required to discriminate among them.
In vitro cross-resistance between trioxaquines and artemisinin
The quiescence mechanism already described in the highly artemisinin-resistant parasite line, F32-ART5, was investigated by recrudescence assays. 15, 16 We observed (Table 1, Figure 3 ) that the F32-ART5 parasite line was able to recrudesce significantly faster than the F32-TEM line, after 48 h of exposure to trioxaquines WT and artemisinin-susceptible, and for F32-ART5 line, K13 mutated and artemisinin resistant. Assays were performed in duplicate on at least three independent experiments with drug or DMSO/excipient as a control. For all the molecules tested, a significant difference (*P , 0.001) was reported between F32-TEM and F32-ART5 using Student's t-test followed by a Tukey adjustment. DHA, dihydroartemisinin. Wilcoxon-Mann-Whitney test, P , 0.05 is considered significant. c At day 30, three of eight F32-TEM cultures recovered. d Non-significant P value due to the number of experiments (n " 2) performed with F32-DU. Paloque et al. Figure 3a ) and PA1103 (Figure 3b) , as previously observed after artemisinin exposure (Figure 3c) . 15, 16 However, differences of times to recovery initial parasitaemia between both lines were not significant for DU2302 (Figure 3d) or DU2303 (Figure 3e ). The two moieties of each trioxaquine ( Figure 1) were also tested separately to analyse their pharmacological involvement. As already reported, 16 F32-ART5 showed in vitro multidrug resistance patterns, including artemisinin and quinoline resistance, with a trend of faster recrudescence than the F32-TEM line. Whatever the results obtained after exposures with the different moieties of each trioxaquine, only both primaquine-based trioxaquines, DU2302 and DU2303 (Table 1, Figures 1 and 3) showed no crossresistance with artemisinin.
DU1302 (
In parallel, we demonstrated a strong cross-resistance between trioxaquines and artemisinin via the RSA 0-3h . Indeed, after 6 h of exposure to dihydroartemisinin or the trioxaquines DU1302 or PA1103, F32-ART5 showed significantly higher survival rates (P , 0.001) compared with F32-TEM (Figure 4 ). Resistance to PA1103 was also confirmed in P. falciparum K13 mutant artemisinin-resistant Cambodian isolates (median survival rates of 100%) compared with K13 WT artemisinin-susceptible Cambodian isolates (median survival rate of 0.3%, P " 0.02) ( Table 2 ). As controls, the median survival rates of K13 mutant artemisinin-resistant and K13 WT artemisinin-susceptible Cambodian isolates exposed to 700 nM dihydroartemisinin were, as expected, also significantly different (30.1% versus 0.2%, P " 0.02). Our data indicated that PA1103 is fully effective against K13 WT artemisinin-susceptible early ring-stages but less active against the same parasite stages of the K13 mutant artemisininresistant lab strain and isolates. These data showed a clear crossresistance between trioxaquines and artemisinin derivatives, despite a hybrid chemical structure that included a quinoline moiety, in K13 mutant artemisinin-resistant isolates.
In vitro selection of the F32-DU trioxaquine-resistant line
To study the phenotype pattern and molecular signatures associated with trioxaquine resistance, we cultured the F32-Tanzania clone, known to be susceptible to the majority of antiplasmodial drugs, for .4 years under a discontinuous and dose-escalating regimen of trioxaquine DU1302, as was done with artemisinin 15, 16 ( Figure 2 ). We observed similar median recrudescence times with F32-DU and F32-ART5 after 48 h of DU1302 treatment (14 days) or after artemisinin treatment (11 and 10 days), which were significantly shorter than for F32-TEM (16 to up to 30 and 21 days) (Table 3) . Furthermore, survival rates expressed by the RSA 0-3h after exposure of the F32-DU parasite line by DU1302, PA1103 and dihydroartemisinin were similar to F32-ART5: 12.2% versus 12.3% (P " 0.645), 8.7% versus 15.3% (P " 0.159) and 10.7% versus 7.2% (P " 0.244), respectively (Table 4 ). In contrast, survival rates appear to be significantly different after drug exposure (regardless of the molecules tested) in F32-DU and F32-TEM, as with F32-ART5 and F32-TEM (Table 4) .
Interestingly, we detected the same non-synonymous mutation of the pfk13 gene (atg . ata, M476I) that coded for the K13 protein propeller domain in the F32-DU whole-genome sequence, which was previously found in the F32-ART5 line (Table 5 ). This finding, confirmed later with a PCR/Sanger sequencing approach, indicated that the discontinuous dose-escalating drug pressure of DU1302 selected in the F32-DU lineage the same K13 mutation in the same gene, as previously observed in the F32-ART5 after artemisinin pressure. 22 The SNP differences found between the strains F32-TEM, F32-DU and F32-ART5, allow confirmation of the absence of parasite cross-contamination between these lines. Only 2 mutations (in genes PF3D7_0110400, PF3D7_1343700) of 10 reported in F32-DU were also found in F32-ART5 (Table 6 ). To our knowledge, this is the first evidence that endoperoxide-based molecules other than artemisinin or its derivatives can select parasites with a mutation in the pfk13 gene. This common K13 mutation clearly explains the strong cross-resistance observed between trioxaquine and artemisinin for both F32-ART5 and F32-DU. Of note, no mutation in genes known to be associated with quinoline resistance (pfcrt and pfmdr-1) was detected. WT pfcrt and pfmdr-1 alleles found in F32-TEM and F32-DU were in accordance with IC 50 values obtained Cross-resistance to endoperoxide-based compounds JAC for chloroquine (Table S1 ). These data are also consistent with previous results reported with F32-ART5 16 and support the hypothesis that the F32-DU parasite line could also resist endoperoxides by a similar quiescence-based mechanism.
Moreover, we previously showed that the hybrid structure of trioxaquines led to a dual mode of action including both haem alkylation (1,2,4-trioxane moiety activity) and the inhibition of haemozoin formation (quinoline moiety activity). 13, 14 However, the two associated pharmacophores could not avoid the in vitro selection of artemisinin-or endoperoxide-resistant parasites. These data indicate that neither the two pharmacophores (each with a high antiplasmodial activity), nor the chemical link between them, allowed trioxaquines to be active against artemisininresistant parasites. We thus demonstrated that (i) artemisininresistant parasites such as F32-ART5 and Cambodian isolates are not susceptible to these new endoperoxides through K13 mutation, and (ii) novel resistance to new endoperoxide-based molecules can be supported by a K13 mutation (as demonstrated with the lineage F32-DU).
Other authors have also shown that a parasite that harbours a K13 mutation can exhibit reduced susceptibility to the antimalarial ozonides depending on the exposure time. 28 Moreover, it was recently reported that K13 mutations significantly compromised the activity of the ozonide OZ277, whereas OZ439 could remain effective against most artemisinin-resistant parasite lines, although a cross-resistance was observed for the mutation I543T, which supports field-based ozonide resistance monitoring. 29 In conclusion, we showed in the present study that resistance to both artemisinins and trioxaquines (cross-resistance) is supported by the same genetic trait (K13 mutation) found in the F32-ART5 artemisinin-resistant parasite line and in Cambodian K13 mutant field isolates. We definitively confirmed this finding by the selection, after a 4 year dose-escalating pressure of a hybrid endoperoxide-based compound, of the F32-DU artemisinin/endoperoxides-resistant parasites that also harbour the M476I mutation in the pfk13 gene, such as the F32-ART lineage. Therefore, all these results raise concerns about the potential development of endoperoxide-based antiplasmodials and the future use of these molecules in our malaria therapeutic arsenal. 4 Urgent investigations are needed to evaluate endoperoxide-based drugs for their ability to select resistant parasites and to lead to cross-resistance with artemisinin and its derivatives. Interestingly, for the mutation reported in the gene PF3D7_0110400, both line F32-DU and F32-ART5 showed the same amino acid modification but from a different nucleotide change (gat . gtt in F32-DU, gat . gtg in F32-ART5
22
).
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